Myeloma Clinical Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Myeloma clinical research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Myeloma Clinical Research Today - Breaking & Trending Today

Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple Myeloma

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma. ....

United States , Hans Lee , Department Of Lymphoma Myeloma , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Myeloma Clinical Research , Multiple Myeloma Clinical Research , Cancer Medicine , Cancer Center , Linker Mm1 Trial , Patients With Relapsed Refractory Multiple Myeloma ,

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma. ....

United States , Hansc Lee , Department Of Lymphoma Myeloma , Myeloma Clinical Research , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Multiple Myeloma Clinical Research , Cancer Medicine , Cancer Center , The University Of Texas Md Anderson Cancer Center , Onclive Tv , Multiple Myeloma , Phase 2 Linker Mm1 Study Nct03761108 , Bcma Cd3 Directed Bispecific Antibody ,

Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma

Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma. ....

United States , Hans Lee , Department Of Lymphoma Myeloma , American Society Of Hematology , University Of Texas Md Anderson Cancer Center , Myeloma Clinical Research , Regeneron Pharmaceuticals Inc , Multiple Myeloma Clinical Research , Cancer Center , Multiple Myeloma , Phase 1 2 Linker Mm1 Study , 2023 Ash Annual Meeting , The University Of Texas Md Anderson Cancer Center ,

Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

Hans Lee, MD, discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and how these data may inform the future of the multiple myeloma treatment paradigm. ....

United States , Hans Lee , Bristol Myers Squibb , Division Of Cancer Medicine , Myeloma Clinical Research , Department Of Lymphoma Myeloma , University Of Texas Md Anderson Cancer Center , Multiple Myeloma Clinical Research , Cancer Medicine , Cancer Center , Allogene Therapeutics , Karyopharm Therapeutics , Legend Biotech , Monte Rosa Therapeutics , Multiple Myeloma ,

Dr Lee on the Investigation of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.
....

United States , Hansc Lee , Division Of Cancer Medicine , University Of Texas Md Anderson Cancer Center , Department Of Lymphoma Myeloma , Myeloma Clinical Research , Multiple Myeloma Clinical Research , Cancer Medicine , Cancer Center ,